On the stock market since 2017, it operates in the world of health and science. It has 23 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 57% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
The stock has been running stronger than the market lately.
Business Quality: Profit power and business quality trail similar companies in the sector.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 32% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 69% a year on average.
Sales run at $7.3M a year. A small number, but proof the product has real buyers.
There is $69.6M in the vault; even if every debt were paid off, $56.2M would remain.
A loss of $17.4M against $7.3M in annual sales.
Measured against its sector, the quality of the business sits below the class average. Report-card grade: 27/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 44/100.
On our five-subject report card, OVID sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: OVID is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (44/100) says the stock isn’t cheap.